Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA; Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA.
Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA; Department of Neurology, Translational Center of Excellence for Neuroepidemiology and Neurology Outcomes Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Epilepsy Behav. 2021 Jan;114(Pt A):107626. doi: 10.1016/j.yebeh.2020.107626. Epub 2020 Dec 9.
Drug compendia are the source of safety prescribing information. We assessed the reporting concordance of drug-drug interactions between hormonal contraception and antiepileptic drugs (AEDs) among eight leading international drug compendia. Antiepileptic drugs reported to interact with ≥1 form of hormonal contraception were reviewed. Scaled concordance was quantified using linearly weighted percent agreement (wPA). Differences in interaction severity rankings between hormonal contraception forms were evaluated using the Wilcoxon signed-rank test. There was high agreement among compendia for interactions of combined hormonal contraception interactions with AEDs (wPA = 0.82-0.84), especially potent enzyme-inducing AEDs (wPA = 0.89). However, concordance was reduced for AED interactions with progestin-only contraception (wPA = 0.69-0.81). Extreme interaction reporting discrepancies were found for less potent enzyme-inducing AEDs. The greatest variability in interaction reporting was observed for injectable and intrauterine contraception (wPA = 0.69 and 0.70, respectively), which are the only hormonal contraception options currently classified as not interacting with enzyme-inducing AEDs. Drug-drug interaction reporting variability can have major clinical implications and highlights critical knowledge gaps in the care of women with epilepsy of childbearing age. Further research on AED-contraceptive interactions is needed to standardize compendia reporting and enhance evidence-based clinical guidelines for women with epilepsy.
药物学专著是安全用药信息的来源。我们评估了 8 种国际主流药物学专著中激素避孕药物与抗癫痫药物(AED)之间药物相互作用报告的一致性。评估了报道与≥1 种激素避孕药物相互作用的抗癫痫药物。采用线性加权百分比一致性(wPA)量化一致性程度。使用 Wilcoxon 符号秩检验评估激素避孕药物之间相互作用严重程度等级的差异。对于激素避孕药与 AED 相互作用,各专著之间具有高度一致性(wPA=0.82-0.84),尤其是强效酶诱导型 AED(wPA=0.89)。然而,对于孕激素避孕药与 AED 相互作用,一致性降低(wPA=0.69-0.81)。对于较弱的酶诱导型 AED,发现了极端的相互作用报告差异。对于注射和宫内避孕,观察到最大的相互作用报告差异(wPA=0.69 和 0.70),这是目前被归类为不与酶诱导型 AED 相互作用的仅有的两种激素避孕方法。药物相互作用报告的可变性可能具有重要的临床意义,并突显了育龄期癫痫女性护理方面的关键知识差距。需要进一步研究 AED-避孕药相互作用,以标准化药物学专著的报告,并为癫痫女性制定基于证据的临床指南。